Hepatology

Martinez explains the pathophysiology and clinical presentation of pruritus in children with cholestatic liver disease as well as treatment options.

Schilsky provides an overview of Wilson disease and describes optimal management strategies, highlighting the importance of early detection and intervention.

Mitchell describes the “paradox” hepatologists face in the management of ALD and the importance of early intervention for improving outcomes.

Banerjee explains the need for noninvasive tests for MASH and reviews promising findings from the RADIcAL-1 trial of LiverMultiScan versus standard of care.

Patients with celiac disease had a 2-fold greater risk of developing a chronic liver disease and experiencing major adverse liver outcomes.

In the RADIcAL-1 trial, mpMRI with LiverMultiScan reduced liver biopsies, led to fewer specialist consultations, and improved MASLD diagnosis rates.

The success of community-based point-of-diagnosis HCV treatment in the NOW trial was attributable to collaborative care with an integrated pharmacy team.

Liver transplants for alcohol-associated liver disease and alcohol-associated hepatitis have increased, but many centers lack necessary resources for care.

In the final segment of this 6-part HCPLive RX Review, experts discuss resmetirom’s significance and what else gives them hope for the future of MASH care.

In the fifth segment of this 6-part HCPLive RX Review, experts discuss the evolving role of noninvasive testing in MASH care.

In the fourth segment of this 6-part HCPLive RX Review, experts discuss the continued importance of diet and exercise for managing MASH.

In the third segment of this 6-part HCPLive RX Review, experts discuss investigational therapies in the MASH pipeline and the use of combination therapy.

In the second segment of this 6-part HCPLive RX Review, experts discuss unmet needs in MASH care, even with resmetirom available as a treatment option.

In the opening segment of this 6-part HCPLive RX Review, experts reflect on resmetirom’s FDA approval for MASH and clinical challenges to implementing it.

Daily screen time exceeding 5 hours was associated with a greater risk of hepatic steatosis in adolescents, partially mediated by BMI.

Findings suggest cardiometabolic risk factors, diet, exercise, and social determinants of health are associated with HRQoL and fibrosis in MASLD.

Patients with PBC and cirrhosis had a higher comorbidity burden and more acute-care events than those without cirrhosis.

In addition to being less likely to become pregnant, women with alcohol-associated hepatitis faced a greater risk of adverse pregnancy outcomes.

Maternal vaccination during pregnancy with the Tdap or seasonal influenza vaccine was associated with greater odds of newborn receipt of the HepB vaccine.

Anouti discusses the new AAP biliary atresia guidance and what it means to him as a patient-advocate who had biliary atresia as an infant.

ChatGPT offered valuable individualized nutritional recommendations for MASLD management, but they did not fully align with established guidelines.

The hepatology month in review spotlights HCPLive’s coverage of hepatic drug development and research about GLP-1 RAs, viral hepatitis, and MASH.

Stine explains key components of a new multidisciplinary MASLD care model and how it improves upon preexisting models.

In adolescents and young adults, gastrointestinal complications from alcohol are increasing at greater rates than other organ systems.

Stine explains the continued need for diet and exercise in MASH and the importance of a multidisciplinary approach to treating these patients.